Key result
Combining PHI and PI-RADSv2 ≤3 yields 98% negative predictive value for prostate cancer grade reclassification.
Why the study?
Combining Prostate Health Index and multiparametric MRI may improve prediction of prostate cancer grade reclassification to reduce unnecessary biopsies in active surveillance.
Does the combination of Prostate Health Index and multiparametric magnetic resonance imaging improve the prediction of prostate cancer grade reclassification in men on active surveillance?
Cohort (n=253)
No
Does the combination of Prostate Health Index and multiparametric magnetic resonance imaging improve the prediction of prostate cancer grade reclassification in men on active surveillance?
Effect estimate: NPV 98%, AUC 0.70
The combination of PHI and mpMRI improves the prediction of prostate cancer grade reclassification in men on active surveillance, potentially avoiding 20% of unnecessary biopsies.
Should not yet alter active surveillance criteria; leaves open need for prospective validation.
No takes yet. Share an insight, caveat, or question.
Schwen et al. (2020) conducted a cohort in Prostate cancer active surveillance (n=253). Combination of Prostate Health Index (PHI) and multiparametric MRI (mpMRI) vs. mpMRI (PI-RADSv2) alone was evaluated on Prostate cancer grade reclassification (Gleason score >6) (NPV 98%, AUC 0.70). Combining a Prostate Health Index cut-off of 25.6 with a PI-RADSv2 score ≤3 increased the negative predictive value for prostate cancer grade reclassification to 98% (AUC 0.70).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: